PRTM

Protembis is a clinical-stage medical device company based in Aachen, Germany, focused on developing the ProtEmbo Cerebral Protection System. The system is designed to reduce the risk of stroke and cognitive decline during transcatheter aortic valve replacement (TAVR) by filtering embolic debris from all three major cerebral arteries. Unlike existing solutions, ProtEmbo is delivered via the left radial artery, providing a low-profile approach that does not interfere with the TAVR procedure. The company is currently conducting the pivotal PROTEMBO trial under an FDA Investigational Device Exemption (IDE) to support global regulatory approvals. Protembis is backed by a consortium of leading European and American life science investors.